Document Detail

Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer.
MedLine Citation:
PMID:  15365078     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Despite the increasing number of publications concerning (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) for staging of esophageal cancer and the increasing availability of this novel diagnostic modality, its exact role in preoperative staging of these tumors is still unknown. The aim of this study was to systematically review the literature regarding the diagnostic performance of FDG-PET in preoperative staging of patients with esophageal cancer, and to calculate summary estimates of its sensitivity and specificity. METHODS: The databases of PubMed, Embase, and Cochrane were searched for relevant studies. Two reviewers independently assessed the methodological quality of each study. A meta-analysis of the reported sensitivity and specificity of each study was performed. RESULTS: Twelve studies met the inclusion criteria. The studies had several design deficiencies. Pooled sensitivity and specificity for the detection of locoregional metastases were 0.51 (95% CI, 0.34 to 0.69) and 0.84 (95% CI, 0.76 to 0.91), respectively. For distant metastases, pooled sensitivity and specificity were 0.67 (95% CI, 0.58 to 0.76) and 0.97 (95% CI, 0.90 to 1.0), respectively. CONCLUSION: FDG-PET showed moderate sensitivity and specificity for the detection of locoregional metastases, and reasonable sensitivity and specificity in detection of distant lymphatic and hematogenous metastases.
H L van Westreenen; M Westerterp; P M M Bossuyt; J Pruim; G W Sloof; J J B van Lanschot; H Groen; J Th M Plukker
Related Documents :
12925088 - Fgd-pet in the follow-up of recurrent colorectal cancer.
12433608 - Usefulness of fdg-positron emission tomography in diagnosing peritoneal recurrence of c...
23942508 - Practice-based evidence to evidence-based practice: building the national radiation onc...
12469828 - Application technique and slurry co-fermentation effects on ammonia, nitrous oxide, and...
24721928 - Rhogdi2 promotes epithelial-mesenchymal transition via induction of snail in gastric ca...
14725728 - Topoisomerase i inhibitors in the combined modality therapy of lung cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  22     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-14     Completed Date:  2004-10-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3805-12     Citation Subset:  IM    
Department of Surgery, University Hospital Groningen, Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Esophageal Neoplasms / pathology*,  radionuclide imaging*
Fluorodeoxyglucose F18 / diagnostic use*
Neoplasm Staging / methods*
Radiopharmaceuticals / diagnostic use*
Sensitivity and Specificity
Tomography, Emission-Computed*
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first...
Next Document:  Biology of gastrointestinal stromal tumors.